LONG BEACH, Calif.--(BUSINESS WIRE)--Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today the publication of a study of its solubilized 5% BPO gel in the June 2008 issue of Journal of Drugs in Dermatology. When compared to twice-daily treatment with a leading BPO/clindamycin antibiotic combination product, the twice-daily monotherapy with the solubilized 5% BPO gel resulted in faster reductions in non-inflammatory and inflammatory lesions. Data shows a significantly greater reduction of non-inflammatory lesions at week 1 and a significantly greater reduction of inflammatory lesions at week 4, with both time points being statistically significant. Both regimens were well-tolerated with comparable levels of patient satisfaction.
